We cut our estimates and lower our valuation range to SEK 75-98. Other than the one-time negative effect from writing down inventory and the accrual of various accounts receivable overdue announced on 7 July, we see q/q growth in BPP sales coupled with lower sales for BD in Q2. The market should be aware of lower BD sales and higher current costs. In our view, the long-term potential (Zimmer, Dentsply Sirona, potential new partners) is unchanged.

https://research.sebgroup.com/corporate/reports/121489

SEB Research

This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.